Piotr Wozniak, MD, a refractive surgeon and dry eye specialist at Tiger Eye Healthcare Clinic in Warsaw, Poland, presented a ...

In the latest episode of The Wills Retina Report, Dr. Regillo and Dr. Hsu discuss why sustained delivery with the port ...

Cataract surgery often addresses one eye at a time, doubling patient travel and the use of resources, further elevating ...

In this episode of NeuroOp Guru in collaboration with Ophthalmology Times, host Andrew G. Lee, MD, is joined by Drew Carey, ...

In this Q&A, Vance Thompson, MD, clears up myths about dry eye and LASIK wearing off, and explains how better screening and ...

Harrow to acquire Tyrvaya, the only FDA-approved nasal spray for dry eye disease, from Viatris for up to $100 million, complementing its cyclosporine product Vevye.

U.S. News & World Report has released its annual list of Best Hospitals, and Bascom Palmer Eye Institute achieved the top ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s ...

Staying on therapy results in better visual outcomes. One implication is that if we have newer drugs that last as long as 180 ...

The FDA has cleared an IND for RAG-1C, a first-in-class saRNA therapy targeting proliferative vitreoretinopathy.

Three cases illustrate treatment switches and extension intervals across retinal vein occlusion, age-related macular degeneration, and diabetic retinopathy.

For a historically underserved and often underrecognized population, the encapsulated cell technology platform represents a rare treatment option in a disease with no prior therapy, but it also ...